Business
Strategic collaboration with Vatic Health Limited
Strategic collaboration with Vatic Health Limited.
About this update from Abingdon Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3112G\n Abingdon Health PLC\n 29 March 2022\n \n \n \n Abingdon Health plc\n (\"Abingdon\" or \"the Company\")\n \n Strategic collaboration with Vatic Health Limited\n Focused on the development, manufacturing and commercialisation of infectious disease lateral flow self-tests\n \n \n York, U.K. 29 March 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Memorandum of Understanding (\"MoU\") with leading diagnostic technology innovator Vatic Health Limited (\"Vatic\"), leading to a commercial agreement for the development and manufacture of a range of lateral flow tests (\"LFTs\") in the area of infectious disease. \n \n \n \n \n Initially Abingdon and Vatic will focus on the development of an innovative influenza LFT, utilising Vatic's proprietary technology platform which identifies proteins via their surface biological mechanisms. The technology has been proven in the development of Vatic's KnowNowᵀ test (Spike Test in USA), an easy-to-use saliva COVID-19 test which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies \"infectious\" or \"active\" copies of the virus which are capable of cell entry and thereby infecting a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive once they are no longer infectious. Furthermore, the unique detection mechanism of the KnowNowᵀ Test has been purposefully designed to be more robust to mutation than traditional antigen tests, making it \"future-proofed\" for ongoing COVID-19 testing. This technology will be applied to the development of an influenza LFT and could have the same potential benefits in terms of accuracy and sensitivity in picking up only those that are infectious, differentiating it from other commercially available tests.\n \n \n \n \n \n Following signing of the MoU, Abingdon and Vatic intend to enter into a longer-term commercial agreement, with both parties developing infectious disease LFTs, Abingdon exclusively manufacturing these LFTs and both parties collaborating on the commercialisation of these innovative new products.\n \n \n &nb...